 Nucleic acid-containing composition, its preparation and use |
| We claim: 1. A composition comprising a deoxyribonucleic acid and a cationic oligopeptide that ... |
|
| Peptide-enhanced cationic lipid transfections |
| OF THE INVENTION The present invention provides improved methods for transfecting eukaryotic cells ... |
|
| Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| It is therefore an object of the present invention to provide a controlled release formulation of a ... |
|
| Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| What is claimed is: 1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3,... |
|
| Substituted indazole-O-glucosides |
| OF THE INVENTION All diabetics, regardless of their genetic and environmental backgrounds, have in ... |
|
| Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| We claim: 1. A method of producing an extracellular hydrolytic Serratia spp. enzyme selected from ... |
|
| Modular assembly of antibody genes, antibodies prepared thereby and use |
| What is claimed is: 1. A polynucleotide molecule encoding an immunoglobulin fragment, said ... |
|
| Cytoplasmic bacteriophage display system |
| The present invention relates, in one aspect, to a display vector comprising DNA encoding a portion ... |
|
| Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions |
| AND ADVANTAGES According to the present invention, a method of diagnosing and determining the ... |
|
| Polyvalent display libraries |
| I. General The present invention is directed to inter alia two related but self-sufficient ... |
|
|
Stable solution of hyaluronate in a balanced salt medium
| Details |
Inventors: Mello, Robert J.; Tew, William P.; Beaty, Narlin B.;
Assignee: Allergan (Waco, TX)
Primary Examiner: Fay; Zohreh
Assistant Examiner:
Attorney, Agent or Firm: Stout, Uxa, Buyan & Mullins, Uxa; Frank J.
A stable physiologic balanced salt solution of a hyaluronate salt, such as sodium hyaluronate, is provided which contains calcium ion, for example, in the form of calcium chloride or calcium acetate, and magnesium ion, for example in the form of magnesium chloride or magnesium acetate, together with sodium chloride, potassium chloride or potassium acetate, sodium acetate, sodium citrate and water, and optionally bicarbonate, dextrose and glutathione disulfide, preservatives and other conventional ingredients employed in irrigating solutions. This solution is used as a visco-elastic ophthalmic device during ophthalmic surgery. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A physiological visco-elastic formulation consisting of sodium hyaluronate in an amount in the range of about 0.
1% to about 5% by weight in a balanced salt aqueous solution consisting of calcium ions present in a concentration in the range of about 2.
6 mM to about 3.
9 mM, magnesium ions present in a concentration in the range of about 1.
2 mM to about 1.
8 mM, potassium ions, chloride ions, acetate ions, citrate ions and sodium ions, other than sodium present as sodium hyaluronate, present in a concentration in the range of about 90 mM to about 110 mM, said formulation being ionically and osmotically balanced and being free of phosphates.
2.
A physiological visco-elastic formulation consisting of sodium hyaluronate in an amount in the range of about 0.
1% to about 5% by weight in an osmotically balanced salt aqueous solution consisting of chloride ions in a concentration in the range of about 59 mM to about 89 mM, potassium ions in a concentration in the range of about 8 mM to about 12 mM, calcium ions in a concentration in the range of about 2.
6 mM to about 3.
9 mM, magnesium ions in a concentration in the range of about 1.
2 mM to about 1.
8 mM, acetate ions in a concentration in the range of about 23 mM to about 34 mM, citrate ions in a concentration in the range of about 4.
6 mM to about 6.
9 mM, and sodium ions, other than sodium present as sodium hyaluronate, present in a concentration in the range of about 90 mM to about 110 mM, said formulation being free of phosphates.
3.
The formulation as defined in claim 2 including sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate and water.
4.
The formulation as defined in claim 2 including sodium chloride, sodium acetate, potassium acetate, magnesium acetate and calcium acetate and water.
5.
The formulation as defined in claim 2 wherein the sodium hyaluronate has a molecular weight of within the range of from about 0.
2.
times.
10.
sup.
6 to about 10.
times
|
|
Gene Therapy 
